Clinical Trial

Two Different Endoscopic Treatments for Rectal Neuroendocrine Neoplasms

Recruiting
View on ClinicalTrials.gov →
Summary
The aim is to compare the safety and efficacy of endoscopic submucosal dissection (ESD) versus endoscopic partial muscle resection( EPMR) for the treatment of rectal neuroendocrine neoplasms (R-NENs), thereby providing guidance for optimizing therapeutic strategies. The investigators retrospectively analyzed consecutive patients with R-NENs who underwent endoscopic resection at our center between January 2020 and February 2026. Patients were assigned to either the ESD group or the EPMR group. Baseline characteristics and perioperative outcomes were compared, including the number of lesions, maximum lesion diameter, single-lesion procedure time, postoperative complications, positive margin rate, pathological staging, lymphovascular invasion, and the need for additional therapies.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-04
Trial Details
NCT Number NCT07612748
Lead Sponsor Jilin University
Conditions Rectal Neuroendocrine Tumors, ESD, EPMR
Enrollment 483 participants
Start Date 2026-06-01
Primary Completion 2026-11-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-03